These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 15332174

  • 1. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
    Rogers MJ.
    Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
    [Abstract] [Full Text] [Related]

  • 2. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ.
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
    Rogers MJ, Watts DJ, Russell RG, Ji X, Xiong X, Blackburn GM, Bayless AV, Ebetino FH.
    J Bone Miner Res; 1994 Jul; 9(7):1029-39. PubMed ID: 7942149
    [Abstract] [Full Text] [Related]

  • 4. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
    Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ.
    J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
    [Abstract] [Full Text] [Related]

  • 5. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ, Thompson K, Gordon S, Rogers MJ.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [Abstract] [Full Text] [Related]

  • 7. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA, Rodan GA.
    Mini Rev Med Chem; 2004 Sep 15; 4(7):711-9. PubMed ID: 15379639
    [Abstract] [Full Text] [Related]

  • 8. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
    Rogers MJ, Xiong X, Brown RJ, Watts DJ, Russell RG, Bayless AV, Ebetino FH.
    Mol Pharmacol; 1995 Feb 15; 47(2):398-402. PubMed ID: 7870050
    [Abstract] [Full Text] [Related]

  • 9. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K, Dunford JE, Ebetino FH, Rogers MJ.
    Biochem Biophys Res Commun; 2002 Jan 18; 290(2):869-73. PubMed ID: 11785983
    [Abstract] [Full Text] [Related]

  • 10. Biochemical and molecular mechanisms of action of bisphosphonates.
    Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J.
    Bone; 2011 Jul 18; 49(1):34-41. PubMed ID: 21111853
    [Abstract] [Full Text] [Related]

  • 11. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E, Löwik C, van der Pluijm G, Papapoulos S.
    J Bone Miner Res; 1999 May 18; 14(5):722-9. PubMed ID: 10320520
    [Abstract] [Full Text] [Related]

  • 12. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG, Rogers MJ.
    Bone; 1999 Jul 18; 25(1):97-106. PubMed ID: 10423031
    [Abstract] [Full Text] [Related]

  • 13. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
    Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ.
    J Bone Miner Res; 1998 Nov 18; 13(11):1668-78. PubMed ID: 9797474
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonates: mode of action and pharmacology.
    Russell RG.
    Pediatrics; 2007 Mar 18; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [Abstract] [Full Text] [Related]

  • 17. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs.
    Plotkin LI, Manolagas SC, Bellido T.
    Bone; 2006 Sep 18; 39(3):443-52. PubMed ID: 16627025
    [Abstract] [Full Text] [Related]

  • 18. [Inhibition of bone resorption by bisphosphonates, heterogeneous group of drugs with different intracellular model of action].
    Stajszczyk M.
    Pol Arch Med Wewn; 2001 Jul 18; 106(1):617-29. PubMed ID: 11928574
    [No Abstract] [Full Text] [Related]

  • 19. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC.
    Cancer; 2000 Jun 15; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [Abstract] [Full Text] [Related]

  • 20. The antitumor potential of bisphosphonates.
    Clézardin P.
    Semin Oncol; 2002 Dec 15; 29(6 Suppl 21):33-42. PubMed ID: 12584693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.